

Acamprosate Calcium

API supporting abstinence in alcohol addiction treatment

Acamprosate Calcium is an established API used in the treatment of alcohol addiction. It supports patients who have already stopped drinking in maintaining abstinence, typically as part of a treatment plan that also includes behavioral therapy and support programs.

Product Highlights

API	Acamprosate Calcium EP
Therapeutic Area	Central Nervous System (CNS) / Addiction Treatment
Mechanism of Action	Believed to help restore the balance between excitatory and inhibitory neurotransmitter systems disrupted by chronic alcohol consumption

Quality

Acamprosate Calcium EP complies with EP specification, with an assay of 98.0–102.0% (dried substance).

Regulatory Status

- › CEP application submitted: May 2026
- › Aarti is actively pursuing European regulatory approval via CEP to support customers in regulated markets
- › No active patent barriers were identified for Acamprosate Calcium, making it suitable for generic development

The Manufacturer: Aarti Drugs Limited



Aarti Drugs Limited is a long-term partner of Biesterfeld and an established pharmaceutical manufacturer. The company has a CEP strategy in place and is open to strategic partnerships across Europe.

Get in Touch

New partnerships and projects in Europe are very welcome — reach out to explore how Acamprosate Calcium could fit your portfolio.

Your contact

For more information feel free to reach to the API experts at Biesterfeld at
api-healthcare@biesterfeld.com

More information:

www.biesterfeld.com

